Litcius/Paper detail

Long-term efficacy and immunogenicity of Ad26.RSV.preF–RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study

Ann R. Falsey, Tessa Hosman, Arangassery Rosemary Bastian, Sjouke Vandenberghe, Eric K. H. Chan, Macaya Douoguih, Esther Heijnen, Christy Comeaux, Benoît Callendret, Mohammed Allaw, Toby Briskin, Daniel C. Brune, Richard Egelhof, John Ervin, Ann R. Falsey, Carolos Fierro, David Fried, Peta-Gay Jackson-Booth, Murray Kimmel, Lorrie McGill, Paul Nugent, Suchet Patel, Barbara Rizzardi, James Ruhlmann, Cynthia Strout, Leslie Tharenos, Timothy P. Vachris, Tyler Wadsworth

2024The Lancet Infectious Diseases26 citationsDOI

Topics & Concepts

ImmunogenicityCypressPlaceboMedicineDouble blindVirologyImmunologyBiologyAntibodyAlternative medicinePathologyBotanyRespiratory viral infections researchCystic Fibrosis Research AdvancesPneumonia and Respiratory Infections
Long-term efficacy and immunogenicity of Ad26.RSV.preF–RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study | Litcius